Retrospective study of non-small cell lung cancer patients treated with Pemborlizumab
Latest Information Update: 11 Oct 2020
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Oct 2020 New trial record
- 21 Sep 2020 Preliminary Results presented at the 45th European Society for Medical Oncology Congress